OSU scientists link rapid bone loss to chemotherapy

July 11, 2001

COLUMBUS, Ohio - Scientists at The Ohio State University Comprehensive Cancer Center say chemotherapy in young, early-stage breast cancer patients often leads to rapid and significant bone loss within months of beginning treatment. Interim findings in the trial were so startling that a part of the study was halted to allow some of the participants to seek intervention with their primary care physicians. The findings are published in the July 15 issue of the Journal of Clinical Oncology.

The study, under the direction of Dr. Charles L. Shapiro, director of breast medical oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and colleagues at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, examined 49 premenopausal women with stage I or II breast cancer. Baseline measures of bone density, estradiol, follicle-stimulating hormone (FSH) and the markers of skeletal turnover osteocalcin and bone-specific alkaline phosphatase were taken within four weeks of beginning adjuvant chemotherapy. Similar measures were taken at six and 12 months after chemotherapy began.

Researchers found 35 of the women (71 percent) lost ovarian function at the end of one year, and, as expected, experienced increases in FSH and decreases in estradiol, changes normally associated with menopause.

What was unexpected, however, was that these same women revealed rapid and dramatic bone loss as early as six months, especially in the femur and spine, and it continued to escalate until the 12 month end point. In contrast, there were no significant decreases in bone mineral density in the 14 patients who retained ovarian function.

"This is truly significant," says Shapiro. "To put it in perspective, a normal post-menopausal woman experiences 1-2 percent bone loss in the spine over the course of a year. The women in our study experienced bone loss four-fold that amount, up to 8 percent in just one year." Shapiro says the bone loss at 12 months was so significant that they had to drop a part of the study that randomized some of the participants to treatment with a nasal spray, calcitonin, and others to a placebo. "An independent monitoring committee examined the 12-month data, and determined it would be unethical to place women on a placebo given the magnitude of the bone loss they were experiencing," Shapiro says.

Previous studies have demonstrated bone loss frequently occurs following chemotherapy, but this study reveals it occurs much earlier than in prior studies. "The results of this study support a role for bone density scans in those women who develop chemotherapy-induced ovarian failure or early menopause, and earlier intervention with calcium, vitamin D, weight-bearing exercise and counseling about the relationship between cigarette smoking, alcohol and bone loss," says Shapiro.

Shapiro says a class of drugs known as bisphosphonates have been shown to mitigate bone loss in women with early stage breast cancer receiving adjuvant chemotherapy. Based on those findings, a Cancer and Leukemia Group B (CALGB) national trial is set to open soon evaluating whether bisphosphonate zolendronic acid (Zometa) will prevent bone loss in premenopausal women receiving adjuvant chemotherapy.
-end-


Ohio State University Wexner Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.